跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41 条关于
“MC5R”
全部
41
临床试验
21
药物
8
机构
1
资讯
11
去年
Palatin's Melanocortin Agonist Shows Promising Results in Phase 2b Diabetic Kidney Disease Trial
去年
Palatin's PL9588 Shows Promise as Dual-Action Glaucoma Therapy with Neuroprotective Effects
2年前
FDA Grants Fast Track Designation to VMT01 for MC1R-Positive Melanoma
去年
Semaglutide Shows Potential for Nerve Regeneration in Children with MC4R-Related Obesity
去年
Palatin Technologies Completes Enrollment in Phase 2 Obesity Trial of Bremelanotide and Tirzepatide Combination
去年
Palatin Technologies Completes Enrollment in Phase 2 Obesity Trial of Bremelanotide with Tirzepatide
10个月前
Palatin Advances Oral MC4R Agonist PL7737 for Obesity Treatment with Promising Preclinical Data
去年
Palatin's Oral MC1R Agonist Shows Promising Results in Phase 2 Ulcerative Colitis Trial
去年
Congruence Therapeutics Advances CGX-926 for Rare Genetic Obesity as Company Presents Novel MC4R Corrector Data
14天前
Superluminal Medicines Raises $60M Series B to Advance MC4R Agonist for Rare Genetic Obesity into the Clinic
第 1 页,共 2 页
上一页
下一页